Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a pre-revenue company: Analyst consensus.
ACCE opinionVaxcyte Inc. Common Stock (PCVX)
Fair value
Not available
ACCE price target
$60.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Price used: $60.43 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
36
out of 100
Analysts
91% buy
11 covering
P/E
0.0x
forward 0.0x
1-year return
+45.3%
Dividend yield
0.00%
Vaxcyte Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Vaxcyte is a clinical-stage vaccine developer whose lead candidates are high-valency pneumococcal conjugate vaccines, VAX-31 and VAX-24, built on its cell-free protein synthesis platform rather than the older carrier-protein chemistry used by Merck and Pfizer. It has no product revenue yet, so the investment case rests on pipeline data and eventual commercial potential against a market that is currently a two-supplier oligopoly. The main near-term catalysts are Phase 3 readouts and immunogenicity data for the higher-valency candidates, which will determine whether the platform can credibly challenge incumbents on coverage and manufacturing economics. At a market capitalization of about $10.3 billion with a return on equity of -36.5%, the stock is priced on those future readouts rather than current earnings, and the composite score of 38/100 and absence from major indices reflect that unresolved binary risk. This name merits a deeper look only if the reader is prepared to underwrite clinical and regulatory outcomes, not the financial profile.
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
moderate
Cash burn with no revenue
Free cash flow is -$669.3M and revenue growth is 0.0%, so the company funds operations from its balance sheet. ROE of -36.5% reflects ongoing losses.
moderate
Elevated short interest
Short interest stands at 11.7% of float, meaning a meaningful minority of holders are betting on a decline. Expect larger price swings around trial or regulatory news.
AI research notes
AI-assisted·How I use AIWritten Oct 14, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
The average analyst target sits 75.6% above the current share price, implying substantial room to run if forecasts prove right.
Debt is light relative to equity, with a debt to equity ratio of 0.09, leaving little balance sheet pressure.
Why it could disappoint
Free cash flow over the last twelve months was negative $669M, meaning the company is consuming cash rather than generating it.
Return on equity of -36.5% shows shareholder capital is being eroded, not put to productive use.
The share count rose 11.6% in the last fiscal year, diluting existing holders' stake in the company.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 3, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where PCVX's valuation models land
Price
$60.43
Model fair valueConfidence: low
about $117
Model
Fair value
Upside
Analyst consensus
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores